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G-protein-coupled receptors (GPCRs) are the largest family of proteins in the human genome. Within the last
year, we have witnessed a relative explosion in the amount of structural information available for the GPCR
family with two new structures of opsin in the presence and absence of transducin peptide, four new struc-
tures of b-adrenergic receptors, and a recent structure of the human adenosine A2A receptor. The new bio-
logical insight being gained, such as the highly divergent extracellular loops and areas of structural conver-
gence within the transmembrane helices, allows us to chart a course for further investigation into this
important class of membrane proteins.Introduction
Cellular recognition and transmission of exogenous signals is
a central requirement for higher-level functionality of multicellular
organisms. Nature has arrived at a few commonmechanisms by
which cells respond to external stimuli: either internalizing the
stimulant directly, as in the case of protons and ions, or by prop-
agating a signal induced by the stimulant through defined
response pathways. One of the most common response path-
ways in the cell is formed by the guanine nucleotide-binding
proteins (G proteins), which are involved in second-messenger
cascades triggered by the G-protein-coupled receptors
(GPCRs), membrane proteins with seven-transmembrane
helices denoted as TM I through TM VII. Until recently, our
atomic-level understanding of GPCRs has been based on
rhodopsin in its inactive state (Palczewski et al., 2000). Although
groundbreaking, it became apparent over the ensuing 8 years
that rhodopsin is a highly specialized member of the GPCR
family that might not be the ideal representative for drawing
generalized conclusions about the other family members
(Figure 1). In the past year, the field of GPCR structural biology
has enjoyed a renaissance, with three new members yielding
to crystallization efforts (Cherezov et al., 2007; Jaakola et al.,
2008; Rasmussen et al., 2007; Rosenbaum et al., 2007; Warne
et al., 2008) and significant inroads made in resolving the acti-
vated state of bovine rhodopsin (Park et al., 2008; Scheerer
et al., 2008) (Table 1; Figure 2). Together these efforts represent
the first examples of what is sure to be a blossoming of informa-
tion for this important class of membrane proteins, and as such
we will review what insights might be gained from a structural
comparison of the different regions of the GPCRs after intro-
ducing the structures themselves.
Rhodopsin and Opsin Structures
Since the initial structure of bovine rhodopsin was solved 8 years
ago, much effort has gone into further characterizing the photo-
cycle of this protein, including the elusive activated structure (Li
et al., 2004; Okada et al., 2004; Palczewski et al., 2000; Salom
et al., 2006). The past year has witnessed great strides in the
rhodopsin field and indeed in GPCRs in general with the publica-
tion of the opsin structure at 2.9 A˚ and opsin bound to a peptide8 Structure 17, January 14, 2009 ª2009 Elsevier Ltd All rights reservfrom transducin (the main conduit by which rhodopsin transmits
signaling information) at 3.2 A˚ (Park et al., 2008; Scheerer et al.,
2008). The opsin structure represents an unliganded form of the
receptor and displays significant structural deviation with
rhodopsin in its inactive form. Interestingly, no significant struc-
tural differences are seen upon binding of opsin to the C-terminal
peptide from transducin. This suggests that in the absence of its
covalently bound ligand, 11-cis-retinal, opsin establishes an
equilibrium close to that of activated receptor that is capable
of binding its signaling partner. These two structures push the
envelope in theGPCR field one step closer to resolving the active
form of the receptor.
The b-Adrenergic Structures
A flurry of activity has occurred within the last year surrounding
b-adrenergic receptor (bAR) structural biology efforts. Two initial
structures of b2AR were released in quick succession, and the
higher-resolution complete model was crystallized as a fusion
protein with T4-lysozyme using a nanovolume cholesterol-
doped lipidic cubic phase crystallization method (Cherezov
et al., 2007). The majority of the protein was observed at 2.4 A˚
resolution, including the extracellular loops and the ligand
binding site, allowing modeling of the receptor’s interactions
with the partial inverse agonist carazolol. Genetic fusing of
T4-lysozyme between TM V and TM VI effectively replaced the
disordered third intracellular loop, increasing the available
surface area potential for crystal contacts. The receptor dis-
played near-native binding characteristics with essentially iden-
tical affinity for antagonists as compared with the nonfusion
protein and a slight increase in affinity for agonists (Rosenbaum
et al., 2007). Structural comparison to the 3.5 A˚ b2AR in complex
with a Fab fragment bound to a structural epitope at the cyto-
plasmic base of TM V and TM VI that was crystallized using
the bicelle crystallization method (Rasmussen et al., 2007)
showed minimal structural deviations from b2AR-T4-lysozyme,
strengthening the assertion that the T4-lysozyme fusion had little
effect on the structural properties of the antagonist bound
receptor. First proposed as a strategy in the crystallization of
lactose permease (Kaback et al., 1994; Prive and Kaback,
1996; Prive et al., 1994), the b2AR-T4 lysozyme structureed
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usefulness of the strategy in structural studies. Furthermore,
the method appears to be quite general, with any membrane
protein possessing a disordered loop potentially being amenable
to this technique. However, because of the importance of this
loop in G protein binding interactions, the fusion protein strategy
will likely not be amenable to structural studies of the signaling
mechanism of GPCRs. Furthermore, the success of this tech-
nique may be dependent on the topology of the intracellular
region, which, as the squid rhodopsin structures suggest,
diverges as a function of altered G protein subtype specificity
(Murakami and Kouyama, 2008; Shimamura et al., 2008).
Figure 1. Phylogenetic Clustering of the
Class A (Rhodopsin-like) GPCRs with
the Known Structures Mapped onto
the Appropriate Cluster
The class A receptors can be divided into four
groups termed a, b, g, and d. The groups can be
further divided according to the ligand binding
characteristics of its members, with the total
number of receptors indicated in parentheses.
Here the a group is divided into amine, opsin,
melatonin, prostaglandin, and MECA (melatonin/
EDG/cannabinoid/adenosine) receptors. The
b group contains peptide receptors, and the g
group contains the chemokine melanin concen-
trating hormone (MCH) receptors and SOG
(somatostatin/opioid/galanin) receptors. Finally,
the d group contains the Mas proto-oncogene
and Mas proto-oncogene-related receptors,
purine binding receptors, and the glycoprotein
receptors (Fredriksson et al., 2003). All GPCR
structures are derived from the a group of recep-
tors as shown.
Table 1. Known X-Ray Structures of GPCRs and Their Associated Binding Partners
Protein or Complex Protein Data Bank Code Resolution Species
Rhodopsin 1GZM, 1HZX, 1JGJ, 1L9H, 1U19, 2I35, 2I36,
2I37, 2J4Y, 2Z73, 2ZIY, 3C9L, 3CAP, 3DQB
2.2–4.2 A˚ Bovine, squid
b2-Adrenergic receptor 2R4R, 2R4S, 2RH1, 3D4S 2.4–3.4 A˚ Human
b1-Adrenergic receptor 2VT4 2.7 A˚ Turkey
Adenosine A2A receptor 3EML 2.6 A˚ Human
G protein a subunit 1AGR, 1AZS, 1AZT, 1BOF, 1CIP, 1GFI, 1GIA,
1TAD, 1TAG, 1TND, 1ZCA, 1ZCB, 2HLB
1.5–2.8 A˚ Rat, dog, bovine,
mouse, human
G protein abg trimer 1A0R, 1GOT, 1GP2, 2TRC 2.0–2.5 A˚ Bovine, rat
G protein/RGS complex 1FQJ, 1FQK, 2GTP, 2IHB, 2IK8, 2ODE, 2PBI, 3C7L 2.0–2.7 A˚ Bovine-rat, human, mouse,
b-Arrestin 1AYR, 1CF1, 1G4M, 1G4R, 1SUJ, 1ZSH, 2R51, 2VGL 1.9–3.3 A˚ Bovine
G protein receptor kinase (GRK) 2ACX, 3C4W, 3C4X, 3C4Z, 3C50 1.8–2.9 A˚ Human, bovine
GRK/G protein complex 1OMW, 2BCJ 2.5–3.1 A˚ Bovine
Opsin/G protein peptide complex 3DQB 3.2 A˚ Bovine
Despite these difficulties, this structure
could very well serve as a harbinger for
the field of GPCR structural biology in
combining the strategy of insertion of
fusion proteins in loops of membrane
proteins to promote crystallizability with
the emerging technology of lipidic cubic
phase crystallization (Caffrey, 2000,
2003; Cherezov et al., 2006; Landau 2003; Landau and Rose-
nbusch, 1996; Nollert et al., 2002).
Shortly after the initial breakthroughs, an additional structure
of b2AR-T4 lysozyme with a stabilizing point mutation, E122W,
was solved in complex with the inverse agonist timolol (Hanson
et al., 2008; Roth et al., 2008). Based on different crystal packing
interactions, this structure established a specific binding site for
cholesterol between transmembrane helices II, III, and IV. This
cholesterol binding interaction (cholesterol consensus motif,
CCM) appears to be conserved across multiple members of
the class A GPCR family based on sequence similarity among
the 4 residues participating in the tightest binding interactionsStructure 17, January 14, 2009 ª2009 Elsevier Ltd All rights reserved 9
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MinireviewFigure 2. Panel of Representative GPCRs Solved to Date
Each group of receptors is represented by one structure, all rendered with the same orientation and color scheme: transmembrane helices are colored light blue,
intracellular regions are colored darker blue, and extracellular regions are brown. Each ligand is colored orange and rendered as sticks, bound lipids are colored
yellow, and the conserved toggle switch tryptophan residue is rendered as spheres and colored green. This figure highlights the observed differences seen in the
extracellular and intracellular domains as well as the small differences seen in the ligand binding orientations.(Hanson et al., 2008). Cholesterol has long been thought to
be involved in modulating membrane protein function by two
fundamentally different mechanisms: in modifying bulk
membrane properties such as fluidity and curvature, or by direct
interactions with the membrane protein in question (Pucadyil
and Chattopadhyay, 2006). The new CCM site is a potential allo-
steric binding site, in close proximity to the orthosteric binding
site of many small-molecule therapeutics targeting a variety of
class A GPCRs. Thus, this finding might open new avenues for
drug discovery by directly targeting this area with sterol-like
molecules that retain binding to the 4 residues comprising the
CCM motif and introducing specificity by designing binding
interactions with less well conserved residues surrounding the
CCM.
The turkey b1AR structure was solved in the presence of cya-
nopindolol, a strong antagonist (Warne et al., 2008). Stabilization
of the protein by systematic mutagenesis coupled to a thermal
stability assay was necessary to achieve high-resolution diffrac-
tion (Serrano-Vega et al., 2008). The overall structure is very
similar to that of human b2AR with the exception of the second
intracellular loop (ICL2), which forms a short helical segment in
b1AR and a random coil in b2AR.
The Adenosine A2A Structure
The recent publication of the adenosine A2A structure at almost
exactly the 1-year anniversary of the initial bAR structures under-
lines the general applicability of the approaches outlined above.
This structure at 2.6 A˚ provides a well-resolved picture of the
adenosine ligand-binding site, which has shifted position relative
to rhodopsin and the bARs and shows even greater helical shifts
relative to rhodopsin than b2AR. Aside from the biological
insights gained from the adenosine A2A structure, it provides
a fundamental validation of the process by which it and two of
the four b-adrenergic structures were generated.10 Structure 17, January 14, 2009 ª2009 Elsevier Ltd All rights reseStructural Comparison
Extracellular Region
Analysis of the extracellular regions of all three representative
subclasses (rhodopsin, adrenergic, adenosine) of GPCRs
reveals a great deal of topological divergence and highlights
the underappreciated importance of this domain (Figure 3). For
instance, rhodopsin has extensive secondary and tertiary struc-
ture in this region, which serves to completely occlude the
binding site from solvent access. The N terminus of rhodopsin
along with extracellular loop 2 (ECL2) forms a four-stranded
b sheet with additional interactions between ECL3 and ECL1
(Figure 3A). There is one disulfide bridge that has been shown
to be essential for the normal function of rhodopsin (Richards
et al., 1995), and there is evidence that incorporating further
disulfide bridges through genetic engineering can enhance the
thermal stability (Standfuss et al., 2007). The extensive tertiary
interactions among all four components of the extracellular
region represent a very well-defined structural unit that severely
restricts access of solvent to the retinal binding pocket.
The extracellular region of the bARs is very open in compar-
isonwith rhodopsin. Themost prominent feature is a short helical
segment within ECL2 that is supported by limited interactions
with ECL1 and two disulfide bridges, one with a random coil
segment of ECL2 C-terminal to the helical stretch and the other
fixing the entire loop to the top of TM III. The random coil section
of ECL2 forms the top of the ligand-binding pocket, which is only
partially occluded by the extracellular region (Figure 3B). In
contrast to rhodopsin, where the entire extracellular region forms
a compact folded unit, ECL3 in the b-adrenergic family forms no
interactions with ECL1 or ECL2 and the entire 28-residue
N terminus is completely disordered in the four structures solved
to date. It would appear that the extracellular region of the
b-adrenergic family has evolved to allow access to the ligand-
binding site. Based on the interactions observed between
ECL2 and the bound ligand, it is possible that this loop is evenrved
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greater access to the binding pocket.
The extracellular region of the adenosine receptors is highly
constrained by four disulfide bridges and multiple polar and
van der Waals interactions among the three loops. Three of the
four disulfide bridges constrain the position of ECL2 by
anchoring the loop to ECL1 and the top of TM III. Nevertheless,
the tip of ECL2 is highly flexible and not observed in the electron
density maps. It appears that the three disulfide bridges serve to
stabilize a short helical segment of ECL2 just N terminal of TM V
(Figure 3C), which presents two important residues, Phe168 and
Glu169, for ligand binding interactions (Figure 4C). ECL3
contains an intraloop disulfide bridge between Cys259 and
Cys262 whose function is unknown; however, based on the
structure, we speculate that this bridge constrains the position
of His264, which forms a polar interaction with Glu169. Thus,
the extracellular region of the adenosine family is structurally
constrained to form multiple ligand binding interactions.
Transmembrane Helices
Sequence conservation among class A GPCRs is highest within
the transmembrane regions. Thus, it is not surprising that the
helical bundle orientation and packing is similar among the struc-
tures solved to date. However, it is instructive to analyze this
region in some detail for two main reasons: (1) through structural
comparison, one can map the regions in the receptors that are
most similar; (2) the areas of structural divergence within the
helical segments can inform differences in receptor pharma-
cology. We have performed an alignment of the transmembrane
regions of all five representativeGPCRs and identified a common
structural core of 97 residues with an average Ca RMSD of 1.3 A˚
Figure 3. Extracellular View of Rhodopsin, b-Adrenergic, and Adenosine A2A Receptors
The ligand in each case is rendered as sticks and colored orange and the toggle switch tryptophan is rendered as van der Waals spheres and colored green. The
extracellular domain in rhodopsin (A) serves to occlude the retinal binding pocket, whereas in both the b-adrenergic (B) and adenosine A2A (C) receptors the extra-
cellular domain is highly constrained and held away from the ligand binding pocket opening.
Figure 4. Ligand Binding Pocket of Rhodopsin, b-Adrenergic, and Adenosine A2A Receptors
Residues interacting with the ligand in each case (orange sticks) are colored as green sticks. Polar interactions where applicable are shown as yellow lines
between the interacting atoms.
(A) The retinal binding pocket relies mainly on hydrophobic interactions in addition to a covalent linkage with TM VII.
(B) The b-adrenergic ligands interact with the receptors through two clusters of polar interactions. The first cluster is shown at the tail of the ligand carazolol, where
the positively charged secondary amine group and b-OH group participate in polar interactions with a conserved glutamate on TM III and asparagine on TM VII.
The second grouping of polar interactions is with the head group of the ligand and a cluster of serine residues on TM V.
(C) The adenosine ligand ZM241385 forms mainly polar interactions between a primary amine group and an asparagine residue on TM VI and a glutamate
on ECL2. A p-stacking interaction between the ligands heterocyclic group and a phenylalanine residue also on ECL2 plays a role in binding affinity.Structure 17, January 14, 2009 ª2009 Elsevier Ltd All rights reserved 11
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Sequence Identity (%) / Sequence Similarity (%) rmsd (A˚)
1U19 3CAP 2RH1 2VT4 3EML
Bovine rhodopsin (PDB code 1U19) 100%/100% 0.0 A˚ 100%/100% 2.3 A˚ 18%/36% 2.1 A˚ 18%/37% 2.1 A˚ 18%/35% 2.4 A˚
Bovine opsin (PDB code 3CAP) 100%/100% 0.0 A˚ 18%/36% 2.6 A˚ 18%/37% 2.7 A˚ 18%/35% 2.8 A˚
Human b2AR (PDB code 2RH1) 100%/100% 0.0 A˚ 64%/79% 0.7 A˚ 29%/44% 2.1 A˚
Turkey b1AR (PDB code 2VT4) 100%/100% 0.0 A˚ 31%/47% 2.1 A˚
Human A2A-adenosine (PDB code 3EML) 100%/100% 0.0 A˚
Percent sequence identity and similarity were calculated using the FatCat server (Ye andGodzik, 2003). The rmsdwas calculated by first aligning struc-
tures using a common core of 97 residues with an average rmsd of 1.3 A˚ over the five vertebrate GPCRs listed. The reported rmsd values are for the
transmembrane helices only. The core region was determined using Pymol structural alignment algorithm and total transmembrane rmsd was calcu-
lated using LSQMAN (DeLano, 2002; Kleywegt and Jones, 1995). PDB indicates Protein Data Bank.(Table 2). Calculation of the root-mean-square deviation (rmsd)
over all residues in the transmembrane helices after aligning
only the common structural core indicates that the non-core resi-
dues tend to be highly structurally divergent, increasing the total
transmembrane rmsd considerably (Table 2). As such, these
divergent positions are likely to be responsible for differences
in signaling and ligand binding properties observed across the
class A receptors.
Ligand Binding Pocket
The position of the antagonist-binding pocket varies significantly
as a function of the receptor. It is useful to compare the two alter-
nate binding pockets with that of rhodopsin, both in terms of
relative position in reference to specific helices and in more
absolute terms using the membrane plane as a reference point.
As was previously described, the b-adrenergic binding pocket is
quite similar to that of rhodopsin (Cherezov et al., 2007). The
position does not vary considerably with alternate ligands or
between different subtypes of different species (Hanson et al.,
2008; Warne et al., 2008). As a representative ligand, the
aliphatic tail of carazolol follows a very similar path as that of
rhodopsin (Figure 4A and 4B). The ligand in both cases extends
from TMVII, where it participates in polar interactions for carazo-
lol and is covalently bound in the case of rhodopsin, to the TM V/
TM VI interface. Here the position of retinal and carazolol deviate
as retinal extends deeper into the receptor to interact with
Trp265 (a tryptophan is in general conserved at this position in
class A receptors and is thought to be involved in receptor
signaling), whereas carazolol forms more extensive interactions
with TM V.
With the recent elucidation of the A2A adenosine structure, we
see that the ligand binding pocket can assume a very different
location to that of rhodopsin and the bARs (Jaakola et al.,
2008). In addition to shifting to the interface of TM VI and TM
VII, ligand ZM241385 forms extensive interactions with ECL2
and is rotated relative to carazolol and retinal, so that the long
axis of the ligand is perpendicular to the plane of the plasma
membrane (Figure 4C). The binding pocket is also much higher
relative to the modeled position of the plasma membrane, with
almost half of the ligand completely exposed to bulk solvent
(Lomize et al., 2006).
Intracellular Loops
Based on sequence conservation and the initial bovine
rhodopsin structure, it has been assumed that a conserved
triplet of residues termed the DRY motif (usually consisting of12 Structure 17, January 14, 2009 ª2009 Elsevier Ltd All rights reseran aspartate or glutamate followed by an arginine and tyrosine),
at the intracellular base of TM III found in most class A GPCRs,
takes part in a conserved interaction with a glutamate residue
at the base of TM VI (Okada et al., 2004; Palczewski et al.,
2000; Vogel et al., 2008). This proposed conserved interaction
is termed the ionic lock and was thought to be an important
component in stabilizing the inactive state of most members of
the class A GPCR family. The determination of the b2AR cast
doubts on this assumption because despite the presence of
the DRY motif and glutamate residue, no interaction was
observed. With the solution of both the b1AR and adenosine
A2A, neither of which has the ionic lock interaction, one can
draw the conclusion that the ionic lock observed in rhodopsin
is not a universal interaction among the class A receptors. The
question remains, however, what is the purpose of the
conserved triplet of residues, if not to stabilize the inactive state
of GPCRs through ionic interactions? It is interesting to note that
the unliganded form of rhodopsin (opsin) undergoes conforma-
tional changes especially in the intracellular region that can
mimic some of the features observed in the other GPCR struc-
tures (Figure 5). For instance, in rhodopsin, helix V extends one
turn below the plane of the membrane, as determined by the
Orientations of Proteins in Membranes database (Lomize et al.,
2006). Upon loss of retinal, however, helix V becomes extended
by two turns, effectively shortening ICL3 and perhaps constrain-
ing the movement of helix VI, pulling it outward and away from
the base of TM III and the DRY motif. Although it is difficult to
interpret this region because of the presence of the T4L fusion
protein, which replaces ICL3, it is apparent that in both b2AR
and A2A, helix V is 1.5 turns longer than that of rhodopsin,
perhaps having a similar effect on TMVI and the ionic lock
(Figure 5). This analysis is substantiated by b1AR, which did
not possess a fusion protein and also does not have an ionic
lock interaction. Instead, in these receptors the DRY region is in-
teracting with ICL2 by means of a polar hydrogen bond between
the aspartate residue and either a serine or tryptophan on the
loop. One interesting correlation points to the type of interaction
in this area having implications for levels of basal activity (Jaa-
kola et al., 2008). For instance, in both A2A adenosine and
b1AR, ICL2 consists of a short helical segment and the DRY
aspartate interacts with a conserved tyrosine at a similar position
on this helix, and both have a low basal activity (Birnbaumer
et al., 1994; Zezula and Freissmuth, 2008). However, despite
the presence of a tyrosine at the same position in b2AR, theved
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Bovine rhodopsin is the only receptor with an intact ionic lock interaction between the E/DRYmotif and glutamate on TM VI. However, in the opsin structures, the
ionic lock is broken and the helical section of TM V is extended considerably relative to the inactive bovine rhodopsin. Human b2AR has a similar-length TM V as
bovine opsin, turkey b1AR, and human A2A adenosine receptors, all of which have a disrupted ionic lock.With the exception of opsin and rhodopsin, the DRYmotif
interacts with ICL2 through a polar interaction between the aspartate residue and either a serine or tyrosine residue on ICL2.DRY aspartate interacts with a serine two positions C terminal to
the conserved tyrosine and has a relatively high level of basal
activity (Birnbaumer et al., 1994). If this correlation holds, our
understanding of the conformational changes that take place
upon agonist binding together with the structural information
already accumulated onGprotein subunits will further our under-
standing of the interactions that take place among different class
A GPCRs and their downstream effectors (Table 1).
Discussion
It is said that form follows function in structural biology. This is
a particularly prescient statement in the context of GPCR struc-
tural biology because this class of receptors has evolved natu-
rally to induce signaling along many pathways dependent on
ligand binding, cellular localization, and allosteric modulation.
This functional diversity, however, is at the core of the difficulties
in structurally resolving aspects of their biology, making devel-
opment of novel approaches a necessity. Within the last year,
we have witnessed a veritable explosion in the amount of struc-
tural information available on this class of pharmaceutically
important integral membrane proteins. Because of this exponen-
tial increase in information over the last year, the field has pro-
gressed from doubting the viability of GPCR structural biologyStructo anticipation of the next receptor to yield to this type of analysis
and new discovery.
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